Armata Pharmaceuticals(US:ARMP) Prnewswireยท2024-08-13 20:05Core Insights - Armata Pharmaceuticals reported financial results for Q2 2024, highlighting advancements in its clinical programs and financial performance [1][2][3]. Clinical Developments - Enrollment in the Tailwind Phase 2 clinical study of inhaled AP-PA02 for patients with Non-Cystic Fibrosis Bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection has been completed, with topline data expected in H2 2024 [2][3]. - The company received $5.25 million in non-dilutive funding from the U.S. Department of Defense to support the Phase 2a diSArm study of intravenous AP-SA02 for Staphylococcus aureus bacteremia [2][3]. - Armata has made progress in bacteriophage science through presentations at industry conferences and has completed the build-out of its cGMP manufacturing facility [2][3]. Financial Performance - Grant revenue for Q2 2024 was $0, compared to approximately $1.0 million in Q2 2023 [4]. - Research and development expenses increased to approximately $8.5 million in Q2 2024 from approximately $8.3 million in Q2 2023 [4]. - General and administrative expenses rose to approximately $3.4 million in Q2 2024, up from approximately $2.4 million in Q2 2023, primarily due to increased stock-based compensation [5]. - Loss from operations for Q2 2024 was $11.9 million, compared to a loss of approximately $9.6 million in Q2 2023 [6]. - As of June 30, 2024, the company held approximately $26.4 million in unrestricted cash and cash equivalents, a significant increase from $13.5 million at the end of 2023 [6]. Company Overview - Armata Pharmaceuticals is focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections, with a pipeline that includes candidates for Pseudomonas aeruginosa and Staphylococcus aureus [7].